<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05087784</url>
  </required_header>
  <id_info>
    <org_study_id>20210920H</org_study_id>
    <nct_id>NCT05087784</nct_id>
  </id_info>
  <brief_title>AlloLife - Life After Transplantation</brief_title>
  <acronym>AlloLife</acronym>
  <official_title>AlloLife - Life After Allogeneic Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universit√§t des Saarlandes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Paoli-Calmettes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Warsaw</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Of Perugia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre for Research and Technology Hellas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Essen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Survivors of allo HCT can experience long-term survival, which is however limited by a number&#xD;
      of late effects. These will be addressed in AlloLife to improve quality of life (QoL) and&#xD;
      survival.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The complex intervention in AlloLife will consist of a set of technically-supported tools&#xD;
      that will enable active care management through the patient and treating physician to improve&#xD;
      QoL.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2024</start_date>
  <completion_date type="Anticipated">June 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Life as measured by the FACT-BMT score</measure>
    <time_frame>12 months</time_frame>
    <description>Change in QoL measured by the FACT BMT score on a continuous scale. The Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) as initially developed by McQuellon RP et al. BMT 1997. It scales between 0 (zero) and 196 on a continuous scale, where higher values refer to higher Quality of Life.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">192</enrollment>
  <condition>Survivorship</condition>
  <condition>Stem Cell Transplant Complications</condition>
  <arm_group>
    <arm_group_label>Intervention:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Complex, technology supported survivorship intervention using wearable devices for patients, supportive patient apps and physician apps for risk prediction. Increased Cardio-oncology visits assigned to risk patients as predicted by the app.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm:</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Wearable device for patients together with a basic patient app providing feedback on the wearable device records and patient information material.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Technology supported, coordinated survivorship care using wearable devices, supportive patient-apps and cardio-oncology physician apps</intervention_name>
    <description>Patient-centered, technology-supported integrated survivorship- and care management</description>
    <arm_group_label>Intervention:</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18&#xD;
&#xD;
          -  Patients with performed allogeneic stem cell transplantation any type of donor, stem&#xD;
             cell source, GVHD prophylaxis or conditioning regimen and at least at day +20 after&#xD;
             HCT.&#xD;
&#xD;
          -  Hematologic Remission after HCT at study entrance, MRD positive patients are allowed&#xD;
             to enter the study&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-3&#xD;
&#xD;
          -  Signature of informed and written consent by the subject or by the subject's legally&#xD;
             acceptable representative for patients under guardianship or trusteeship to&#xD;
             participate in the study&#xD;
&#xD;
          -  Access to an internet connected device (smartphone/tablet/computer)&#xD;
&#xD;
          -  Able to understand and communicate in the respective language&#xD;
&#xD;
          -  Consent to use a wearable device through the time of the study&#xD;
&#xD;
          -  Consent to use a chatbot application for both healthcare data exchange and psychologic&#xD;
             intervention&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Missing consent to use a wearable device and contribute personal data collected at the&#xD;
             point of life to the study&#xD;
&#xD;
          -  ECOG performance status of 4&#xD;
&#xD;
          -  Relapse of the disease at study inclusion&#xD;
&#xD;
          -  Uncontrolled systemic infection&#xD;
&#xD;
          -  Diagnosis of a secondary malignancy requiring systemic therapy&#xD;
&#xD;
          -  Reported ongoing severe depression or potential suicidal ideation&#xD;
&#xD;
          -  Vulnerable patients such as: minor, persons deprived of liberty, persons in Intensive&#xD;
             Care Unit unable to provided informed consent prior to the intervention&#xD;
&#xD;
          -  Other ongoing interventional protocol that might interfere with the current study&#xD;
             primary endpoint&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Norbert Graf, MD</last_name>
    <phone>+49- 6841/16-28397</phone>
    <email>norbert.graf@uks.eu</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 20, 2021</study_first_submitted>
  <study_first_submitted_qc>October 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The IPD Sharing Plan will be developed during the project.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

